Literature DB >> 24119076

The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.

K I Abdul-Jalil1, K M Sheehan, J Kehoe, R Cummins, A O'Grady, D A McNamara, J Deasy, O Breathnach, L Grogan, B D P O'Neill, C Faul, I Parker, E W Kay, B T Hennessy, P Gillen.   

Abstract

AIM: To date, there is no uniform consensus on whether tumour regression grade (TRG) is predictive of outcome in rectal cancer. Furthermore, the lack of standardization of TRG grading is a major source of variability in published studies. The aim of this study was to evaluate the prognostic impact of TRG in a cohort of patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation therapy (CRT). In addition to the Mandard TRG, we utilized four TRG systems modified from the Mandard TRG system and applied them to the cohort to assess which TRG system is most informative.
METHOD: One-hundred and fifty-three patients with a T3/T4 and/or a node-positive rectal cancer underwent neoadjuvant 5-fluorouracil-based CRT followed by surgical resection.
RESULTS: Thirty-six (23.5%) patients achieving complete pathological response (ypCR) had a 5-year disease-free survival (DFS) rate of 100% compared with a DFS rate of 74% for 117 (76.5%) patients without ypCR (P = 0.003). The Royal College of Pathologists (RCPath) TRG best condenses the Mandard five-point TRG by stratifying patients into three groups with distinct 5-year DFS rates of 100%, 86% and 67%, respectively (P = 0.001). In multivariate analysis, pathological nodal status and circumferential resection margin (CRM) status, but not TRG, remained significant predictors of DFS (P = 0.002, P = 0.035 and P = 0.310, respectively).
CONCLUSION: Our findings support the notion that ypCR status, nodal status after neoadjuvant CRT and CRM status, but not TRG, are predictors of long-term survival in patients with locally advanced rectal cancer. Colorectal Disease
© 2013 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  Cancer; oncology; radiology

Mesh:

Substances:

Year:  2014        PMID: 24119076     DOI: 10.1111/codi.12439

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  22 in total

1.  College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer.

Authors:  Hai-Yang Chen; Li-Li Feng; Ming Li; Huai-Qiang Ju; Yi Ding; Mei Lan; Shu-Mei Song; Wei-Dong Han; Li Yu; Ming-Biao Wei; Xiao-Lin Pang; Fang He; Shuai Liu; Jian Zheng; Yan Ma; Chu-Yang Lin; Ping Lan; Mei-Jin Huang; Yi-Feng Zou; Zu-Li Yang; Ting Wang; Jin-Yi Lang; Guy R Orangio; Vitaliy Poylin; Jaffer A Ajani; Wei-Hu Wang; Xiang-Bo Wan
Journal:  Oncologist       Date:  2021-02-22

2.  Phosphatidylinositol 3-kinase CB association with preoperative radiotherapy response in rectal adenocarcinoma.

Authors:  Wei-Dong Yu; Yi-Fan Peng; Hong-Da Pan; Lin Wang; Kun Li; Jin Gu
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

3.  Prognostic influence of histopathological regression patterns in rectal adenocarcinoma receiving neoadjuvant therapy.

Authors:  Ma Jesús Fernández-Aceñero; Lourdes Estrada Muñoz; Javier Sastre Varela; Juan Antonio Corona Sánchez; Cristina Díaz Del Arco; Beatriz García Paredes; Sofía Córdoba Largo; Laura Del Puerto Nevado
Journal:  J Gastrointest Oncol       Date:  2017-02

4.  Preoperative FOLFOX in resectable locally advanced rectal cancer can be a safe and promising strategy: the R-NAC-01 study.

Authors:  Nobuki Ichikawa; Shigenori Homma; Tohru Funakoshi; Masahiro Hattori; Masanori Sato; You Kamiizumi; Kazuyoshi Omori; Masaru Nomura; Ryoichi Yokota; Masahiko Koike; Hirofumi Kon; Keisa Takeda; Hiroyuki Ishizu; Kunihiro Hirose; Daisuke Kuraya; Takahisa Ishikawa; Ryohei Murata; Hiroaki Iijima; Futoshi Kawamata; Tadashi Yoshida; Yosuke Ohno; Nozomi Minagawa; Norihiko Takahashi; Akinobu Taketomi
Journal:  Surg Today       Date:  2019-03-05       Impact factor: 2.549

5.  Is there a role for adjuvant chemotherapy in pathological complete response rectal cancer tumors following neoadjuvant chemoradiotherapy?

Authors:  Ravit Geva; Eran Itzkovich; Sivan Shamai; Einat Shacham-Shmueli; Viacheslav Soyfer; Joseph M Klausner; Hagit Tulchinsky
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-22       Impact factor: 4.553

6.  Multiphoton microscopy for tumor regression grading after neoadjuvant treatment for colorectal carcinoma.

Authors:  Lian-Huang Li; Zhi-Fen Chen; Xing-Fu Wang; Shuang-Mu Zhuo; Hong-Sheng Li; Wei-Zhong Jiang; Guo-Xian Guan; Jian-Xin Chen
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

7.  A Modified Classification of Prognostic Factors Based on Pathological Stage and Tumor Regression Grade in Patients with Rectal Cancer Who Receive Preoperative Chemoradiotherapy.

Authors:  Toshiyuki Suzuki; Sotaro Sadahiro; Akira Tanaka; Kazutake Okada; Gota Saito; Hiroshi Miyakita; Takeshi Akiba; Hiroshi Yamamuro
Journal:  Oncology       Date:  2017-07-21       Impact factor: 2.935

8.  Pathologic response grade after long-course neoadjuvant chemoradiation does not influence morbidity in locally advanced mid-low rectal cancer resected by laparoscopy.

Authors:  Filippo Landi; Eloy Espín; Victor Rodrigues; Francesc Vallribera; Aleix Martinez; Cecile Charpy; Francesco Brunetti; Daniel Azoulay; Nicola de'Angelis
Journal:  Int J Colorectal Dis       Date:  2016-10-19       Impact factor: 2.571

9.  Thymidine phosphorylase and hypoxia-inducible factor 1-α expression in clinical stage II/III rectal cancer: association with response to neoadjuvant chemoradiation therapy and prognosis.

Authors:  Shuhan Lin; Hao Lai; Yuzhou Qin; Jiansi Chen; Yuan Lin
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

10.  Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

Authors:  Zachary S Morris; Sandeep Saha; William J Magnuson; Brett A Morris; Jenna F Borkenhagen; Alisa Ching; Gayle Hirose; Vanesa McMurry; David M Francis; Paul M Harari; Rick Chappell; Stuart Tsuji; Mark A Ritter
Journal:  Cancer       Date:  2016-05-20       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.